Vertex Pharmaceuticals (VRTX) Change in Acquisitions & Divestments (2009 - 2026)

Vertex Pharmaceuticals has reported Change in Acquisitions & Divestments for 18 years, with the latest figure at $75.5 million in Q2 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 95.89% year-over-year to $75.5 million in Q2 2026; TTM through Jun 2026 was $4.7 billion, a 22.2% decrease from a year earlier, with the FY2025 full-year figure at $5.9 billion, up 32.06% from the prior year.
• Change in Acquisitions & Divestments was $75.5 million for Q2 2026 at Vertex Pharmaceuticals, down from $2.2 billion in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $2.2 billion in Q1 2026, with the low at $50.0 million in Q1 2023.
• Average Change in Acquisitions & Divestments over 5 years is $800.4 million, with a median of $597.3 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2026: Change in Acquisitions & Divestments soared 1321.0% in 2024, then plunged 95.89% in 2026.
• Over 5 years, Change in Acquisitions & Divestments stood at $484.1 million in 2022, then slumped by 54.95% to $218.1 million in 2023, then soared by 569.51% to $1.5 billion in 2024, then retreated by 25.23% to $1.1 billion in 2025, then slumped by 93.08% to $75.5 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $75.5 million (Q2 2026), $2.2 billion (Q1 2026), and $1.1 billion (Q4 2025), per Business Quant data.